Company news: Shire, Sanofi

Share this article:
Shire announced Wednesday that it is looking to expand the indication for its ADHD medication Vyvanse. The company is seeking approval for use of the stimulant as a maintenance drug for children between the ages of 6 and 17. It is currently cleared for maintenance therapy among adults. Approval would make it the only stimulant approved for maintenance among this age group. FDA's action date is April 29, 2013.

Sanofi is expected to clarify layoff plans at meetings September 25 and October 3, reported Reuters, which attributed the information to union sources. Reuters' sources said they expect Sanofi to cut about 2,500 research and support jobs in France. Sanofi told Reuters meeting dates had not been set, but that it will present its employment plans to the works council this month.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.